Zenocutuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Zenocutuzumab
Accession Number
DB15559
Description

Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).

Type
Biotech
Groups
Investigational
Synonyms
  • Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized clone mcla-128 .gamma.1-chain), disulfide with humanized clone mcla-128 light chain, dimer
  • Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
  • Zenocutuzumab
External IDs
  • MCLA-128

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Zenocutuzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Zenocutuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zenocutuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Zenocutuzumab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Zenocutuzumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Zenocutuzumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zenocutuzumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Zenocutuzumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Zenocutuzumab.
AvelumabThe risk or severity of adverse effects can be increased when Avelumab is combined with Zenocutuzumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
AE72RB1W1X
CAS number
1969309-56-5

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentMetastatic Breast Cancer1
1, 2RecruitingTreatmentNRG1 Fusion / NSCLC Harboring NRG1 Fusion / Pancreatic Cancer Harboring NRG1 Fusion / Solid Tumours Harboring NRG1 Fusion1
Not AvailableAvailableNot AvailableMalignant Neoplasm of Pancreas / Non-Small Cell Lung Carcinoma (NSCLC) / NRG1 / NRG1 Fusion / Solid Tumor, Unspecified, Adult1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 17, 2019 09:15 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates